193 related articles for article (PubMed ID: 33207783)
21. Annular atrophic lichen planus induced by anti-HER2 antibodies.
Chawla S; Turner N; Terlizzo M; Heelan K
Australas J Dermatol; 2021 May; 62(2):210-212. PubMed ID: 33216943
[TBL] [Abstract][Full Text] [Related]
22. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Sharma P; Kimler BF; O'Dea A; Nye L; Wang YY; Yoder R; Staley JM; Prochaska L; Wagner J; Amin AL; Larson K; Balanoff C; Elia M; Crane G; Madhusudhana S; Hoffmann M; Sheehan M; Rodriguez R; Finke K; Shah R; Satelli D; Shrestha A; Beck L; McKittrick R; Pluenneke R; Raja V; Beeki V; Corum L; Heldstab J; LaFaver S; Prager M; Phadnis M; Mudaranthakam DP; Jensen RA; Godwin AK; Salgado R; Mehta K; Khan Q
Clin Cancer Res; 2021 Feb; 27(4):975-982. PubMed ID: 33208340
[TBL] [Abstract][Full Text] [Related]
23. Metformin and Breast Cancer: Current Findings and Future Perspectives from Preclinical and Clinical Studies.
Corleto KA; Strandmo JL; Giles ED
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543182
[TBL] [Abstract][Full Text] [Related]
24. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer.
Magno E; Bussard KM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542380
[TBL] [Abstract][Full Text] [Related]
25. Aromatase Inhibitor Therapy Increases the Risk of New-Onset Atrial Fibrillation in Patients With Breast Cancer.
Ho I; Wong CK; Wong YK; Lam TH; Sze-Him Leung I; Lin M; Tak-Wai Lui D; Kwok WC; Tam CC; Chan YH; Chan EWY; Tse HF
JACC Asia; 2024 Feb; 4(2):150-160. PubMed ID: 38371283
[TBL] [Abstract][Full Text] [Related]
26. Towards a New Generation of Hormone Therapies: Design, Synthesis and Biological Evaluation of Novel 1,2,3-Triazoles as Estrogen-Positive Breast Cancer Therapeutics and Non-Steroidal Aromatase Inhibitors.
Rashdan HRM; Abdelrahman MT; De Luca AC; Mangini M
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256921
[TBL] [Abstract][Full Text] [Related]
27. What Role do Androgens Play in Endometrial Cancer?
Maček P; Molinari N; Sobočan M; Knez J
J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836575
[TBL] [Abstract][Full Text] [Related]
28. Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators.
Richard V; Nair MG; Jaikumar VS; Jones S; Prabhu JS; Kerin MJ
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834918
[TBL] [Abstract][Full Text] [Related]
29. CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients.
Crucitta S; Ruglioni M; Lorenzini G; Bargagna I; Luculli GI; Albanese I; Bilancio D; Patanè F; Fontana A; Danesi R; Del Re M
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831647
[TBL] [Abstract][Full Text] [Related]
30. MOF negatively regulates estrogen receptor α signaling
Zhang X; Yang Y; Li D; Wu Z; Liu H; Zhao Z; Zhu H; Xie F; Li X
Front Oncol; 2022; 12():868866. PubMed ID: 36212422
[TBL] [Abstract][Full Text] [Related]
31. Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis.
Porras L; Ismail H; Mader S
Cells; 2021 Oct; 10(11):. PubMed ID: 34831189
[TBL] [Abstract][Full Text] [Related]
32. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
[TBL] [Abstract][Full Text] [Related]
33. A Fluorometric CYP19A1 (Aromatase) Activity Assay in Live Cells.
Heidary DK; Kriger SM; Hachey AC; Glazer EC
ChemMedChem; 2021 Sep; 16(18):2845-2850. PubMed ID: 34224206
[TBL] [Abstract][Full Text] [Related]
34. AdipoRon and Other Adiponectin Receptor Agonists as Potential Candidates in Cancer Treatments.
Nigro E; Daniele A; Salzillo A; Ragone A; Naviglio S; Sapio L
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070338
[TBL] [Abstract][Full Text] [Related]
35. Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.
Vivarelli S; Candido S; Caruso G; Falzone L; Libra M
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291603
[TBL] [Abstract][Full Text] [Related]
36. Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target.
Caciolla J; Bisi A; Belluti F; Rampa A; Gobbi S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33207783
[TBL] [Abstract][Full Text] [Related]
37. New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.
Cepa M; Correia-da-Silva G; da Silva EJ; Roleira FM; Borges M; Teixeira NA
BMC Cell Biol; 2008 Jul; 9():41. PubMed ID: 18652661
[TBL] [Abstract][Full Text] [Related]
38. Aromatase, aromatase inhibitors, and breast cancer.
Chumsri S; Howes T; Bao T; Sabnis G; Brodie A
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):13-22. PubMed ID: 21335088
[TBL] [Abstract][Full Text] [Related]
39. Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer.
Ahmad I; Shagufta
Eur J Med Chem; 2015 Sep; 102():375-86. PubMed ID: 26301554
[TBL] [Abstract][Full Text] [Related]
40. Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update.
Gobbi S; Rampa A; Belluti F; Bisi A
Anticancer Agents Med Chem; 2014 Jan; 14(1):54-65. PubMed ID: 23869785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
